Achieve Life Sciences Inc. (ACHV)’s Financial Results Comparing With Allakos Inc. (NASDAQ:ALLK)

Achieve Life Sciences Inc. (NASDAQ:ACHV) and Allakos Inc. (NASDAQ:ALLK) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achieve Life Sciences Inc.N/A0.0012.69M-8.120.00
Allakos Inc.N/A0.0043.54M-0.900.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Achieve Life Sciences Inc. and Allakos Inc.


Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net MarginsReturn on EquityReturn on Assets
Achieve Life Sciences Inc.0.00%-114.6%-93.5%
Allakos Inc.0.00%0%0%


The Current Ratio and Quick Ratio of Achieve Life Sciences Inc. are 4.6 and 4.6 respectively. Its competitor Allakos Inc.’s Current Ratio is 24.4 and its Quick Ratio is 24.4. Allakos Inc. can pay off short and long-term obligations better than Achieve Life Sciences Inc.

Institutional and Insider Ownership

The shares of both Achieve Life Sciences Inc. and Allakos Inc. are owned by institutional investors at 26.7% and 94.1% respectively. Achieve Life Sciences Inc.’s share held by insiders are 4.97%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W)Performance (M)Performance (Q)Performance (HY)Performance (Y)Performance (YTD)
Achieve Life Sciences Inc.-8.68%61.33%45.78%-23.66%-80.94%100%
Allakos Inc.2.27%1.68%-31.19%1.32%0%-22.29%

For the past year Achieve Life Sciences Inc. has 100% stronger performance while Allakos Inc. has -22.29% weaker performance.


Allakos Inc. beats Achieve Life Sciences Inc. on 4 of the 6 factors.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.